Tianjin Tianyao Pharmaceuticals Co., Ltd.

Equities

600488

CNE000001840

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.91 CNY +0.51% Intraday chart for Tianjin Tianyao Pharmaceuticals Co., Ltd. +5.39% -20.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jinyao Pharma Unit's Fluconazole Chloride Passes Regulatory Evaluation MT
Jinyao Pharma Unit's Metoclopramide Hydrochloride Injection Passes Regulatory Evaluation MT
Jinyao Pharma Unit's Clindamycin Phosphate Passes Drug Regulator's Evaluation MT
Jinyao Pharmaceutical's Drugs Chosen for China's Centralized Procurement Bid MT
Jinyao Pharmaceutical Gets Nod to Market Travoprost MT
Tianyao Pharma’s Brain Injury Drug Passes Generic Drug Consistency Test MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jinyao Pharmaceutical Unit's Methylcobalamin Injection Passes Drug Regulator's Evaluation MT
Jinyao Pharmaceutical Gets Nod to Market Two Raw Drug Materials MT
Tianjin Tianyao Pharmaceuticals Co., Ltd.(XSSC:600488) added to S&P Global BMI Index CI
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jinyao Pharmaceutical Unit's Tumor Drug Passes Regulatory Evaluation MT
Jinyao Pharmaceutical Gets Nod for Marketing Application of Raw Drug Material MT
Tianjin Tianyao Pharma Receives 35 Million Yuan in Government Subsidies MT
Tianyao Pharma Registers Inhalation Drug MT
Jinyao Pharmaceutical's Unit Gets Nod to Topical Cream's Registration MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tianyao Pharma Joins Bid to Have Edema Drug Added to China’s Drug Procurement Program MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Jinyao Pharmaceutical Unit's Diazepam Injection Passes Consistency Evaluation MT
Jinyao Pharmaceutical Unit Gets Regulatory Nod for Anti-Allergy Drug MT
Jinyao Pharmaceutical Signs Desinging and Construction Agreement With Tianjin Pharmaceutical Design Institute MT
Chart Tianjin Tianyao Pharmaceuticals Co., Ltd.
More charts
Jinyao Pharmaceutical Co Ltd, formerly Tianjin Tianyao Pharmaceuticals Co., Ltd., is a China-based company mainly engaged in the research and development, production and sales of corticosteroids and amino acid APIs and preparations. The Company's main products include dexamethasone series, prednisone series, methylprednisolone series, betamethasone series and more than 40 varieties of corticosteroid raw materials, 23 varieties of amino acid raw materials, and 16 dosage forms such as tablets, injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, and inhalation preparations. The Company mainly operates in the domestic market and overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 600488 Stock
  4. News Tianjin Tianyao Pharmaceuticals Co., Ltd.
  5. Jinyao Pharmaceutical Gets Nod for Marketing Application of Raw Drug Material